Immunolocalization of somatostatin receptor 2 (SSTR2) could predict the therapeutic efficacy of somatostatin analogues (SSAs) in neuroendocrine tumors (NETs). The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.